Version 2.5.2.0

Abstract

Grant Number:	5U54CA091405-020004
Project Title:	Pilot--AH receptor in human breast tumors

PI Information:	Name	Email	Title
	JENSEN, ROY A.	rjensen@kumc.edu	DIRECTOR

Abstract: The Ah receptor (AhR) is a cytosolic protein which is well studied for its mediation of toxic responses to environmental polyhalogenated aromatic hydrocarbons (PAH) such as dioxin. Our preliminary investigation on the expression of AhR protein in human breast carcinoma (HBC) cell lines has revealed that the AhR is dramatically up-regulated in these cells, in direct proportion to their malignancy. The research we are proposing aims to establish a correlation between the AhR expression and the degree of malignancy in samples of human breast tumors of varying stages of pathogenesis (benign proliferative lesions, ductal carcinoma in situ, invasive mammary carcinoma), in comparison to normal mammary tissue. The expression of AhR mRNA and protein in these specimens will be assessed by in Situ hybridization and immunohistochemical staining, respectively. Results of immunobiochemical analysis will be correlated to the respective histopathological grade and history (clinical stage hormone receptor and lymph node status). The proposed research aims to identify the AhR over-expression as one of the critical determinants in invasion and tumor metastasis cascade by establishing a correlation between its expression and that of these determinants. If well-established, AhR could be used as an independent prognostic, and as an early biomarker for determining the degree for possible early intervention.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
aromatic hydrocarbon receptor, breast neoplasm, receptor expression
biomarker, cooperative study, neoplasm /cancer invasiveness, prognosis, tumor progression
human tissue, immunocytochemistry, in situ hybridization, tissue /cell culture

Institution:	VANDERBILT UNIVERSITY
	Medical Center
	NASHVILLE, TN 372036869
Fiscal Year:	2002
Department:
Project Start:
Project End:
ICD:	NATIONAL CANCER INSTITUTE
IRG:	ZCA1

---